|
AR038605A1
(es)
*
|
2002-02-25 |
2005-01-19 |
Elan Pharm Inc |
Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
AU2003270330B2
(en)
*
|
2002-09-06 |
2009-07-30 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component C5
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
NO346070B1
(no)
*
|
2003-02-10 |
2022-01-31 |
Biogen Ma Inc |
Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
PT1729810T
(pt)
*
|
2004-04-02 |
2018-11-22 |
Swedish Orphan Biovitrum Ab Publ |
Métodos de redução da agregação de il-ira
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006055871A2
(en)
*
|
2004-11-19 |
2006-05-26 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
|
WO2006096461A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
|
AU2006247039B2
(en)
|
2005-05-19 |
2011-03-03 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
EA014025B1
(ru)
*
|
2005-09-12 |
2010-08-30 |
Новиммун С.А. |
Композиции антитела против cd3
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
|
SI2359834T1
(sl)
|
2006-03-15 |
2017-02-28 |
Alexion Pharmaceuticals, Inc. |
Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
KR20090060453A
(ko)
*
|
2006-09-25 |
2009-06-12 |
메디뮨 엘엘씨 |
안정화된 항체 제제 및 그것의 용도
|
|
CA2665567C
(en)
*
|
2006-10-06 |
2012-07-03 |
Amgen Inc. |
Stable formulations
|
|
CA2666492C
(en)
|
2006-10-20 |
2012-07-17 |
Douglas Rehder |
Stable polypeptide formulations
|
|
EP2114451A2
(en)
*
|
2007-01-09 |
2009-11-11 |
Wyeth a Corporation of the State of Delaware |
Anti-il-13 antibody formulations and uses thereof
|
|
RU2009134128A
(ru)
*
|
2007-02-12 |
2011-03-20 |
Лассаад БУЖБЕЛЬ (TN) |
Сукралоза в стерильном растворе без консервантов
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
ES2707815T3
(es)
*
|
2007-06-14 |
2019-04-05 |
Biogen Ma Inc |
Formulaciones de anticuerpo natalizumab
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
CN106443002A
(zh)
*
|
2007-10-22 |
2017-02-22 |
贝克顿·迪金森公司 |
评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
PT2271382E
(pt)
|
2008-04-15 |
2013-05-07 |
Grifols Therapeutics Inc |
Ultrafiltração em dois andares/diafiltração
|
|
CN102202655B
(zh)
|
2008-08-27 |
2013-06-19 |
默沙东公司 |
基因工程抗IL-23p19抗体的冻干制剂
|
|
TWI516501B
(zh)
*
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
AU2009319856A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Abbvie Inc. |
Stable antibody compositions and methods for stabilizing same
|
|
WO2010077045A2
(en)
*
|
2008-12-29 |
2010-07-08 |
Samyang Corporation |
Pharmaceutical composition of lyophilized formulation and preparation method of the same
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
WO2010121141A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
|
RU2560701C2
(ru)
*
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
|
HRP20160530T1
(hr)
*
|
2009-09-17 |
2016-07-29 |
Baxalta Incorporated |
Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
|
|
ES2725200T3
(es)
*
|
2009-10-09 |
2019-09-20 |
Armagen Inc |
Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
CN107496917B
(zh)
|
2010-02-26 |
2021-06-11 |
诺沃—诺迪斯克有限公司 |
包含稳定抗体的组合物
|
|
HUE050858T2
(hu)
|
2010-04-16 |
2021-01-28 |
Biogen Ma Inc |
VLA-4 ellenes antitestek
|
|
MX2012013586A
(es)
|
2010-05-28 |
2013-01-24 |
Novo Nordisk As |
Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
|
|
EP3170508B1
(en)
|
2010-06-04 |
2019-11-13 |
Wyeth LLC |
Vaccine formulations
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US8795658B2
(en)
|
2010-09-17 |
2014-08-05 |
Baxter International Inc. |
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
ES2997080T3
(en)
|
2010-10-25 |
2025-02-14 |
Biogen Ma Inc |
Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
|
|
AU2011325974B2
(en)
|
2010-11-11 |
2016-10-27 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-TNFalpha antibody liquid formulations
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
CA2830806C
(en)
|
2011-03-31 |
2020-05-12 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
PH12013502442A1
(en)
*
|
2011-05-26 |
2018-03-21 |
Glaxo Smithkline Biologicals Sa |
Inactivated dengue virus vaccine
|
|
EP2726090B1
(en)
|
2011-07-01 |
2020-01-01 |
Biogen MA Inc. |
Arginine - free tnfr : fc- fusion polypeptide compositions
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
AU2013212587B2
(en)
*
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
RU2644214C2
(ru)
*
|
2012-03-26 |
2018-02-08 |
Санофи |
СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
MX377841B
(es)
|
2013-11-21 |
2025-03-11 |
Genmab As |
Formulación liofilizada de conjugado de anticuerpo-fármaco.
|
|
US9932591B2
(en)
|
2013-12-18 |
2018-04-03 |
University Of Delaware |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
US20210322549A1
(en)
*
|
2015-07-17 |
2021-10-21 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Natalizumab
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
BR112018013407A2
(en)
|
2015-12-30 |
2018-12-18 |
Kodiak Sciences Inc. |
antibodies and conjugates thereof
|
|
JP2019505520A
(ja)
|
2016-01-13 |
2019-02-28 |
ゲンマブ エー／エス |
抗体およびその薬物コンジュゲートの製剤
|
|
ES2797298T3
(es)
|
2016-02-10 |
2020-12-01 |
Becton Dickinson France |
Procedimiento para evaluar la estabilidad de una formulación a base de proteína
|
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
EP3459527B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
|
US20210177957A1
(en)
|
2017-12-06 |
2021-06-17 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
CA3081144A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
SG11202008242XA
(en)
|
2018-03-02 |
2020-09-29 |
Kodiak Sciences Inc |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
IL276896B2
(en)
|
2018-03-05 |
2024-06-01 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
EP3761953A1
(en)
|
2018-03-08 |
2021-01-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
EP3773694A4
(en)
*
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Antibody formulation
|
|
EP3773696A4
(en)
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Stable formulations of therapeutic antibody
|
|
WO2019198099A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Dr. Reddy's Laboratories Limited |
Stable antibody formulation
|
|
CA3099547A1
(en)
|
2018-05-07 |
2019-11-14 |
Reshma Abdulla RANGWALA |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
KR102848349B1
(ko)
|
2018-06-04 |
2025-08-21 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
|
|
MY209122A
(en)
|
2018-06-08 |
2025-06-23 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
WO2019246273A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
KR20210024082A
(ko)
|
2018-06-25 |
2021-03-04 |
제이씨알 파마 가부시키가이샤 |
단백질 함유 수성 액제
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
BR112021009287A2
(pt)
|
2018-11-20 |
2021-10-26 |
Janssen Biotech, Inc. |
Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
|
|
KR20240169145A
(ko)
|
2018-12-19 |
2024-12-02 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
|
|
US12409221B2
(en)
|
2018-12-24 |
2025-09-09 |
Grand Theravac Life Sciences (Nanjing) Co., Ltd. |
Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
|
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
CN114126647A
(zh)
*
|
2019-06-07 |
2022-03-01 |
阿尔金克斯有限公司 |
适用于皮下施用的FcRn抑制剂的药物制剂
|
|
AU2020291508A1
(en)
*
|
2019-06-11 |
2022-01-06 |
Macrogenics, Inc. |
Pharmaceutical formulations of bi-specific diabodies and use of the same
|
|
WO2021022249A1
(en)
*
|
2019-08-01 |
2021-02-04 |
Momenta Pharmaceuticals, Inc. |
Fcrn antibodies and methods of use thereof
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021124793A1
(ja)
*
|
2019-12-16 |
2021-06-24 |
ニプロ株式会社 |
凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
JP2023512446A
(ja)
*
|
2020-01-13 |
2023-03-27 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
|
|
EP4096802A4
(en)
*
|
2020-01-29 |
2024-07-03 |
Merck Sharp & Dohme LLC |
METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
US20230340131A1
(en)
*
|
2020-11-12 |
2023-10-26 |
Dr. Reddy’S Laboratories Limited |
Stable aqueous high concentration formulation of integrin antibody
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
CA3258004A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/HSA BONDING MOLECULES AND METHODS OF USE
|
|
TW202504919A
(zh)
|
2023-05-30 |
2025-02-01 |
美商派拉岡醫療公司 |
α4β7整合素抗體組合物及使用方法
|